难治性免疫性血小板减少性紫癜不同治疗方法的疗效比较  

The Clinical Efficacy of Rituximab Therapy for the Treatment of Refractory Immune Thrombocytopenic Purpura

作　　者：张莉[1] 钱樱[1] 程澍[1] 游建华[1] 李军民[1] 沈志祥[1] 

机构地区：[1]上海交通大学医学院附属瑞金医院血液科,上海200025

出　　处：《中国临床医学》2008年第4期522-523,527,共3页Chinese Journal of Clinical Medicine

摘　　要：目的:比较免疫性血小板减少性紫癜(ITP)不同治疗方法的疗效,探讨利妥昔单抗治疗难治性ITP的安全性和有效性。方法:125例ITP患者,分别应用糖皮质激素、丙球、达那唑、免疫抑制剂等治疗,其中5例难治性ITP患者应用利妥昔单抗375mg.m-2,静脉输注,每周一次,连用4周。结果:ITP的一线治疗总反应率达70%。利妥昔单抗治疗的5例难治性ITP患者,2例获完全缓解(CR),1例获部分缓解(PR),1例微小反应(MR),1例没有反应。没有急性和迟发的毒性反应。结论:利妥昔单抗可能是治疗难治性ITP安全、有效的药物。Objective：To compare the efficacy of different treatments for idiopathic thrombocytopenic purpura（ITP） ,and to e valuate the safety and validity of rituximab in patients with refractory ITP. Methods： Steroids, IV immunoglobulin （IVIg） ,danazol ,or immunosuppressive drugs were administered to 125 patients with ITP. We used rituximab at 375 mg/m^2 , IV, weekly for a total of four doses in5 patients with refractory ITP. Results： The response tares to the first-line treatment for ITP was 70%. We used rituximab in 5 patients with refractory ITP,complete remission（CR） was achieved in 2 patients, partial remission（PR） in 1 ,minimal response（MR） in 1, and 1 patients was classified as therapeutic failures. There was no risk of adverse events. Conclusion：Rituximab therapy is effective and safe in patients with refractory ITP.

关 键 词：利妥昔单抗 抗CD20 难治性ITP 

分 类 号：R554.6[医药卫生—血液循环系统疾病]